TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36436704
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of CoronaVac (N = 134)
Study: 36436704
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of BNT162b2 (N = 133)
Study: 36436704
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of ChAdOx1 (N = 127)
Study: 36437418
Drug: Inactivated SARS-CoV-2
Normalized name: Inactivated SARS-Cov-2 Vaccine
DrugBank: Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences) (DB15863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated SARS-CoV-2 vaccine (BBIBP-CorV), 2 doses on days 0 and 21
Study: 36438589
Drug: Suprachoroidal injection
Normalized name: NIACINAMIDE 5 g in 100 g SUPRACHOROIDAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprachoroidal injection of triamcinolone acetonide (TA) 4 mg/0.1 mL
Study: 36438753
Drug: Fermented PV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented PV (70 mL daily for 8 weeks)
Study: 36438753
Drug: Placebo (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (70 mL daily for 8 weeks)
Study: 36440533
Drug: BNT162b2 vaccine
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 vaccine (none, one or two doses)
Study: 36440533
Drug: BNT162b2 vaccine
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 vaccine (fully vaccinated)
Study: 36441357
Drug: PF-06462700 (equine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06462700 (equine anti-thymocyte immunoglobulin) administered intravenously at 40 mg/kg/day for 4 days
Study: 36441736
Drug: Oral olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral olanzapine (OLA)
Study: 36441736
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo (PL)
Study: 36442665
Drug: Exposure-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based cognitive behavioral therapy
Study: 36442892
Drug: Intravenous OP-724
Normalized name: OP-1
DrugBank: Eptotermin alfa (DB11631)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Intravenous OP-724 infusion at a dosage of 280 mg/m²
Study: 36442892
Drug: Intravenous OP-724
Normalized name: OP-1
DrugBank: Eptotermin alfa (DB11631)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Intravenous OP-724 infusion at a dosage of 380 mg/m²
Study: 36443171
Drug: CUD-002 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CUD-002 vaccine consisting of dendritic cells loaded with mRNA encoding personalized tumor neoantigens
Study: 36444224
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention initiated during chemotherapy (group A)
Study: 36444224
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention initiated after chemotherapy (group B)
Study: 36444374
Drug: BGF (budesonide/glycopyrronium/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGF (budesonide/glycopyrronium/formoterol fumarate dihydrate) 320/14.4/10 µg
Study: 36444834
Drug: Unmarried patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unmarried patients receiving reperfusion treatment
Study: 36445410
Drug: Intratumoral V937
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral V937 + intravenous pembrolizumab 2 mg/kg Q3W
Study: 36445467
Drug: Buccal wall
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal wall thickness
Study: 36445882
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (DA) and iron supplements as per guidelines
Study: 36445944
Drug: Fenofibrate (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (oral PPAR-α agonist)
Study: 36446452
Drug: Neo-adjuvant therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-adjuvant therapy, surgery and adjuvant chemotherapy
Study: 36446452
Drug: Post-treatment complications
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment complications
Study: 36448227
Drug: Nelarabine continuous
Normalized name: Nelarabine
DrugBank: Nelarabine (DB01280)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nelarabine continuous infusion (CI) for 5 days (120 hours) at escalating doses from 100 to 800 mg/m2
Study: 36448274
Drug: 10% human
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% human intravenous immunoglobulin (IVIg) BT595, total dose of 2 g/kg body weight over 2 or 5 days
Study: 36450289
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for adherence and depression (CBT-AD) delivered by a nurse, conducted once weekly for 12 sessions.
Study: 36450386
Drug: Selective internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective internal radiation therapy (SIRT) followed by nivolumab (240 mg every 2 weeks for up to 24 doses)
Study: 36450938
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green (ICG) at a dose of 5 mg/kg 24 hours prior to surgery
Study: 36451114
Drug: Intensive inpatient
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive inpatient treatment program (APT + VITA)
Study: 36451175
Drug: Decentralized PWUD-HCV
Normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decentralized PWUD-HCV care model using pangenotypic direct acting antivirals (DAAs) for HCV treatment.
Study: 36451242
Drug: Fimasartan 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan 60 mg/amlodipine 10 mg + rosuvastatin 20 mg (FMS/ALD + RSV)
Study: 36451242
Drug: Fimasartan 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan 60 mg/amlodipine 10 mg (FMS/ALD)
Study: 36451242
Drug: Fimasartan 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan 60 mg + rosuvastatin 20 mg (FMS + RSV)
Study: 36451252
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab (IVR) injections (0.5 mg/0.05 mL)
Study: 36451252
Drug: Intravitreal conbercept
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal conbercept (IVC) injections (0.5 mg/0.05 mL)
Study: 36451848
Drug: Dupilumab, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab, a monoclonal antibody that blocks the shared receptor component for interleukin-4 and interleukin-13.
Study: 36452171
Drug: BL10 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: BL10 gel
Study: 36452171
Drug: EMLA gel
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA gel
Study: 36452901
Drug: AGT103-T autologous
Normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGT103-T autologous T cell therapy
Study: 36452951
Drug: Psychotropic medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic medications usage.
Study: 36453122
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline injection (pain group)
Study: 36453122
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline injection (control group)
Study: 36453667
Drug: Pilates intervention,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilates intervention, details on dosage and duration not available
Study: 36454054
Drug: Immunomodulatory and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulatory and/or immunosuppressive (IM/IS) drugs
Study: 36454054
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment with IM/IS drugs (Control)
Study: 36455228
Drug: Trotabresib 30
Normalized name: Trotabresib
DrugBank: Trotabresib (DB17421)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trotabresib 30 mg/day on days 1-4 before surgery, followed by maintenance trotabresib 45 mg/day 4 days on/24 days off after surgery
Study: 36455412
Drug: Cobimetinib 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobimetinib 60 mg once daily for 21 days followed by a 7-day break and concurrent intravenous atezolizumab 840 mg every 2 weeks (Cohort A)
Study: 36456200
Drug: N-acetyl-l-leucine (NALL)
Normalized name: N-acetyl-l-leucine
DrugBank: L-Acetylleucine (DB16956)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-l-leucine (NALL) administered orally at 4 g/d for patients ≥13 years, weight-tiered doses for patients 6-12 years for 6 weeks.
Study: 36456200
Drug: N-acetyl-l-leucine (NALL)
Normalized name: N-acetyl-l-leucine
DrugBank: L-Acetylleucine (DB16956)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-l-leucine (NALL)
Study: 36456573
Drug: Ganetespib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganetespib (150 mg/m) in combination with standard chemotherapy
Study: 36456573
Drug: Standard neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard neoadjuvant chemotherapy (NAC)
Study: 36457860
Drug: EPP-AF® (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPP-AF® (200 mg/day for 4 weeks)
Study: 36458825
Drug: Rifampicin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (600 mg)
Study: 36459100
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise training; details on dosage and duration not available.
Study: 36459284
Drug: Pamiparib 60
Normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamiparib 60 mg orally twice daily in 28-day continuous cycles
Study: 36459673
Drug: Axatilimab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axatilimab (3 mg/kg given once every 4 weeks)
Study: 36459994
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of rhu-GM-CSF
Study: 36460027
Drug: Acoziborole (960
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acoziborole (960 mg single dose)
Study: 36460537
Drug: Two-dose HPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose HPV vaccination program
Study: 36460537
Drug: One-dose HPV
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-dose HPV vaccination program
Study: 36460794
Drug: Opaganib 500
Normalized name: Opaganib
DrugBank: Opaganib (DB12764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opaganib 500 mg BID
Study: 36460794
Drug: Opaganib (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opaganib (up to 750 mg BID)
Study: 36461087
Drug: Community-wide mass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-wide mass drug administration (cMDA) program
Study: 36461750
Drug: Renin-angiotensin-aldosterone system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin-angiotensin-aldosterone system inhibitors or beta-blockers
Study: 36461912
Drug: Rice Bran
Normalized name: Rice bran
DrugBank: Rice bran (DB14361)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice Bran (RB) supplementation (15 g/day)
Study: 36463104
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg and gemcitabine 1,250 mg/m²
Study: 36463173
Drug: Family Treatment
Normalized name: AQP family protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family Treatment Drug Court (FTDC)
Study: 39697397
Drug: Medications for
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications for Opioid Use Disorder (MOUD)
Study: 36463180
Drug: Tobramycin inhalation
Normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin inhalation solution (TIS) once daily (OD) for 1 year
Study: 36463214
Drug: Telemedicine-based program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemedicine-based program (PARTNER UP) providing access to oral pre-exposure prophylaxis (PrEP) and medication for opioid use disorder (MOUD) through syringe services programs (SSPs). Initial in-person visit followed by weekly telemedicine visits in month 1 and monthly visits until month 6.
Study: 36463561
Drug: Ixazomib-based triple-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib-based triple-drug therapy
Study: 36465905
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Radium-223
Study: 36466215
Drug: Emotional Awareness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emotional Awareness and Expression Therapy (EAET) class
Study: 36467452
Drug: Bosutinib 100
Normalized name: bosutinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosutinib 100 mg QD to 400 mg QD
Study: 36467452
Drug: Bosutinib treatment
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bosutinib treatment
Study: 36467815
Drug: Tyrosine kinase
Normalized name: Protein-tyrosine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitor de-escalation or discontinuation
Study: 36468635
Drug: BMAC intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMAC intra-articular injection combined with subchondral BMAC injection
Study: 36468635
Drug: BMAC intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMAC intra-articular injection alone
Study: 36469095
Drug: Post-transplant CD45RA-depleted
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-transplant CD45RA-depleted donor lymphocyte infusions (DLI)
Study: 36469103
Drug: Standard clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard clinical measures (e.g., Nine-Hole Peg Test [9HPT]).
Study: 36469250
Drug: Kollidon VA64®-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kollidon VA64®-based eliapixant formulation (400 mg; fasted)
Study: 36469250
Drug: Immediate-release eliapixant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release eliapixant
Study: 36469250
Drug: Two amorphous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two amorphous solid dispersion (ASD) formulations
Study: 36469250
Drug: Suspension-based formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension-based formulation
Study: 36469321
Drug: Pacritinib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pacritinib (400 mg on day 1 followed by 200 mg twice daily on days 2-14)
Study: 36469840
Drug: Adavosertib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adavosertib monotherapy in patients with epithelial ovarian cancer
Study: 36470149
Drug: Inhaled corticosteroid-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid-containing therapy
Study: 36470745
Drug: Non-opioid analgesics
Normalized name: Non-opioid analgesics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-opioid analgesics (NSAID, paracetamol, metamizole)
Study: 36470745
Drug: Non-opioid analgesics
Normalized name: Non-opioid analgesics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-opioid analgesics
Study: 36470745
Drug: Non-opioid analgesics
Normalized name: Non-opioid analgesics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-opioid analgesics before end of surgery
Study: 36470745
Drug: Opioid doses
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid doses
Study: 36470974
Drug: PAC-1 at
Normalized name: PAC-1
DrugBank: PAC-1 (DB13048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAC-1 at 750 mg/day
Study: 36471059
Drug: Colon capsule
Normalized name: Sus scrofa colon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colon capsule endoscopy (CCE) as an alternative to CT colonography
Study: 36471059
Drug: Colon capsule
Normalized name: Sus scrofa colon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colon capsule endoscopy (CCE) as an alternative to AA colonoscopy
Study: 36471142
Drug: Protamine administration
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protamine administration at a rate of 25 mg·min
Study: 36471142
Drug: Protamine:heparin ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protamine:heparin ratio of 0.3
Study: 36471142
Drug: Protamine:heparin ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protamine:heparin ratio of 0.5
Study: 36471222
Drug: Single 300-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 300-mg oral dose of tucatinib
Study: 36471253
Drug: Capsaicin 8%
Normalized name: CAPSAICIN 8% PATCH KIT,4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin 8% (Qutenza®) patch applied at three time intervals
Study: 36471891
Drug: Trauma-informed yoga
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-informed yoga intervention (6-week, twice-weekly sessions)
Study: 36472134
Drug: zolpidem tartrate
Normalized name: Zolpidem Tartrate
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: zolpidem tartrate extended-release 6.25 mg
Study: 36472300
Drug: High-specific-activity I-131
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-specific-activity I-131 meta-iodobenzylguanidine (dose: ~18.5 GBq (~500 mCi))
Study: 36472579
Drug: exercise treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: exercise treatment
Study: 36472579
Drug: liraglutide treatment
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: liraglutide treatment
Study: 36472719
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation (OAC) treatment including direct oral anticoagulants (DOAC) and vitamin K antagonists (VKA)
Study: 36472719
Drug: OAC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC therapy in anaemic patients
Study: 36472728
Drug: Relugolix (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relugolix (loading dose 360 mg at Day -14, then 120 mg/day until Day -1; followed by 120 mg/day with apalutamide 240 mg from Day 1 to Day 28)
Study: 36472728
Drug: Relugolix +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relugolix + Apalutamide (120 mg/day of relugolix with 240 mg of apalutamide from Day 1 to Day 28)
Study: 36472728
Drug: Relugolix monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relugolix monotherapy
Study: 36472876
Drug: Elaboration on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elaboration on common errors in patient treatment combined with individualized mailed feedback
Study: 36472904
Drug: Call for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Call for Life Uganda (CFLU) interactive voice response tool providing daily pill reminders, preappointment reminders, symptom reporting, and health promotion tips.
Study: 36473121
Drug: Colchicine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1 mg loading dose followed by 0.5 mg/day until discharge) plus atorvastatin 80 mg
Study: 36473121
Drug: Colchicine plus
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine plus atorvastatin
Study: 36473633
Drug: Tralokinumab treatment
Normalized name: tralokinumab
DrugBank: Tralokinumab (DB12169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tralokinumab treatment
Study: 36474017
Drug: Leucine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucine (2 g)
Study: 36474266
Drug: Higher daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher daily AChE levels
Study: 36474435
Drug: c.1342C>G, g.41635A>G
Approvals — FDA: no, EMA: no, PMDA: no
Description: c.1342C>G, g.41635A>G and c.2699C>T polymorphisms
Study: 36474510
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (group M)
Study: 36475114
Drug: Dexamethasone 0.2
Normalized name: dexamethasone 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.2 mg/kg intravenously daily (n = 70)
Study: 36475114
Drug: Dexamethasone 6
Normalized name: dexamethasone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 6 mg daily (n = 72)
Study: 36476135
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg once daily for 17 weeks
Study: 36476605
Drug: Telemonitoring group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemonitoring group using continuous glucose monitor (CGM), insulin pen, activity tracker, and smartphone applications.
Study: 36476605
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care group using blinded CGM for the first and last 20 days and a blinded insulin pen for the entire period.
Study: 36477458
Drug: Early ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Early ibuprofen treatment
Study: 36477870
Drug: Avapritinib 300
Normalized name: avapritinib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avapritinib 300 mg once daily orally
Study: 36477975
Drug: Azacitidine monotherapy
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine monotherapy
Study: 36478334
Drug: Zolbetuximab 800
Normalized name: Zolbetuximab
DrugBank: Zolbetuximab (DB15118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolbetuximab 800 mg/m² intravenous
Study: 36479110
Drug: CCRT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCRT treatment
Study: 36479231
Drug: CPI-613 (devimistat)
Normalized name: CPI-1205
DrugBank: CPI-1205 (DB14581)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPI-613 (devimistat) combined with radiation therapy (RT)
Study: 36479375
Drug: Offering continual
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Offering continual social services as a potential solution.